Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now small index

Breast Cancer Risk clinical trials

2 of 5 indexed Breast Cancer Risk trials are currently recruiting.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Breast Cancer Risk: 5 US clinical trials tracked, 2 recruiting.

Breast Cancer Risk is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. The most active sponsor is Georgetown University, running 1 of these trials.

Enrollment posture brief

Registry condition breast-cancer-risk

OPEN 2 | RECR 40% | LATE 0 | EARLY 0 | RANK #3391 | SPON 1

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Breast Cancer Risk (this)40%
Open-enrollment share among volume-matched conditions near Breast Cancer Risk

Breast Cancer Risk lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Breast Cancer Risk on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Breast Cancer Risk is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Breast Cancer Risk research.

    Georgetown University accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical Breast Cancer Risk enrolment sits around 560 participants.

    Median target enrolment is 560 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.

  4. Breast Cancer Risk splits between interventional and observational designs.

    3 interventional and 2 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase Distribution

Phase data not available

Named interventions

Most-linked intervention names on Breast Cancer Risk records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Community peer coaching Behavioral
1 trials
PeACE Behavioral
1 trials
Health Surveys Other
1 trials
tirzepatide Drug
1 trials
Educational video Behavioral
1 trials
Saliva sample Genetic
1 trials
Artificial Intelligence (AI) Device
1 trials
Magnetic resonance imaging (MRI) Procedure
1 trials

US sites by state

Facility locations filed on Breast Cancer Risk trials. A trial with sites in several states counts in each.

New Jersey 2 trials
Massachusetts 2 trials
Illinois 2 trials
Washington 1 trials
Texas 1 trials
New York 1 trials
Kansas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Breast Cancer Risk page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Cancer Risk condition card totals 5 registered trials; most-linked intervention Community peer coaching; top US site state New Jersey. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.